Recent advances in therapeutic probiotics: insights from human trials
- PMID: 40261032
- PMCID: PMC12160572
- DOI: 10.1128/cmr.00240-24
Recent advances in therapeutic probiotics: insights from human trials
Abstract
SUMMARYRecent advances in therapeutic probiotics have shown promising results across various health conditions, reflecting a growing understanding of the human microbiome's role in health and disease. However, comprehensive reviews integrating the diverse therapeutic effects of probiotics in human subjects have been limited. By analyzing randomized controlled trials (RCTs) and meta-analyses, this review provides a comprehensive overview of key developments in probiotic interventions targeting gut, liver, skin, vaginal, mental, and oral health. Emerging evidence supports the efficacy of specific probiotic strains and combinations in treating a wide range of disorders, from gastrointestinal (GI) and liver diseases to dermatological conditions, bacterial vaginosis, mental disorders, and oral diseases. We discuss the expanding understanding of microbiome-organ connections underlying probiotic mechanisms of action. While many clinical trials demonstrate significant benefits, we acknowledge areas requiring further large-scale studies to establish definitive efficacy and optimal treatment protocols. The review addresses challenges in standardizing probiotic research methodologies and emphasizes the importance of considering individual variations in microbiome composition and host genetics. Additionally, we explore emerging concepts such as the oral-gut-brain axis and future directions, including high-resolution microbiome profiling, host-microbe interaction studies, organoid models, and artificial intelligence applications in probiotic research. Overall, this review offers a comprehensive update on the current state of therapeutic probiotics across multiple domains of human health, providing insights into future directions and the potential for probiotics to revolutionize preventive and therapeutic medicine.
Keywords: microbiota-organ axis; oral-gut-brain axis; probiotic; randomized clinical trials; systemic disease; therapy.
Conflict of interest statement
The authors declare no conflict of interest.
References
-
- Metchinikoff E. 1908. The prolongation of life; optimistic studies. G.P. Putnam’s Sons, New York and London.
-
- Organization FaAOotUNaWH . 2002. Health and nutritional properties of probiotics in food including powder milk with live lactic acid bacteria. Rome, Italy: FAO. https://openknowledge.fao.org/handle/20.500.14283/y6398e.
-
- Hill C, Guarner F, Reid G, Gibson GR, Merenstein DJ, Pot B, Morelli L, Canani RB, Flint HJ, Salminen S, Calder PC, Sanders ME. 2014. The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic. Nat Rev Gastroenterol Hepatol 11:506–514. doi: 10.1038/nrgastro.2014.66 - DOI - PubMed
-
- Proctor LM, Creasy HH, Fettweis JM, Lloyd-Price J, Mahurkar A, Zhou W, Buck GA, Snyder MP, Strauss JF III, Weinstock GM, White O, Huttenhower C, The Integrative HMP (iHMP) Research Network Consortium . 2019. The integrative human microbiome project. Nature 569:641–648. doi: 10.1038/s41586-019-1238-8 - DOI - PMC - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
